Difficulties in calculating productivity costs: Work disability associated with borderline personality disorder

Value in Health

Volumn 11, Issue 4, 2008, Pages 637-644

  Van Asselt, Antoinette D I ^a   Dirksen, Carmen D ^a   Arntz, Arnoud ^b   Severens, Johan L ^a,b  

^a MAASTRICHT UNIVERSITY MEDICAL CENTER   (Netherlands)

^b MAASTRICHT UNIVERSITY   (Netherlands)

Author keywords

Borderline personality; Friction costs; Human capital; Productivity costs; Work disability

Indexed keywords

ADULT; AGED; ARTICLE; BOOTSTRAPPING; BORDERLINE STATE; COMPARATIVE STUDY; ECONOMIC EVALUATION; FEMALE; FRICTION COST METHOD; HUMAN; HUMAN CAPITAL METHOD; MAJOR CLINICAL STUDY; MALE; NETHERLANDS; NONPARAMETRIC TEST; PRIORITY JOURNAL; PRODUCTIVITY; PSYCHOTHERAPY; SOCIETY; WORK DISABILITY;

EID: 47749140055     PISSN: 10983015     EISSN: 15244733     Source Type: Journal    
DOI: 10.1111/j.1524-4733.2007.00288.x     Document Type: Article

References (41)

1. Rice DP, Cooper BS. The economic value of human life. Am J Public Health Nations Health 1967 57 : 1954 66.
2. Koopmanschap MA, Rutten FF, van Ineveld BM, van Roijen L. The friction cost method for measuring indirect costs of disease. J Health Econ 1995 14 : 171 89.
3. Borghouts JA, Koes BW, Vondeling H, Bouter LM. Cost-of-illness of neck pain in The Netherlands in 1996. Pain 1999 80 : 629 36.
4. Goeree R, O'Brien BJ, Blackhouse G, et al. The valuation of productivity costs due to premature mortality: a comparison of the human-capital and friction-cost methods for schizophrenia. Can J Psychiatry 1999 44 : 455 63.
5. Huscher D, Merkesdal S, Thiele K, et al. Cost of illness in rheumatoid arthritis, ankylosing spondylitis, psoriatic arthritis and SLE in Germany. Ann Rheum Dis 2006 65 : 1175 83.
6. Hutubessy RC, van Tulder MW, Vondeling H, Bouter LM. Indirect costs of back pain in the Netherlands: a comparison of the human capital method with the friction cost method. Pain 1999 80 : 201 7.
7. Kaitelidou D, Ziroyanis PN, Maniadakis N, Liaropoulos LL. Economic evaluation of hemodialysis: implications for technology assessment in Greece. Int J Technol Assess Health Care 2005 21 : 40 6.
8. Liu JL, Maniadakis N, Gray A, Rayner M. The economic burden of coronary heart disease in the UK. Heart 2002 88 : 597 603.
9. Lofland JH, Locklear JC, Frick KD. Different approaches to valuing the lost productivity of patients with migraine. Pharmacoeconomics 2001 19 : 917 25.
10. Norum J, Holtmon M. Adjuvant fluorouracil, epirubicin and cyclophosphamide in early breast cancer: is it cost-effective? Acta Oncol 2005 44 : 735 41.
11. Oliva J, Lobo F, Lopez-Bastida J, et al. Indirect costs of cervical and breast cancers in Spain. Eur J Health Econ 2005 6 : 309 13.
12. van Beeck EF, van Roijen L, Mackenbach JP. Medical costs and economic production losses due to injuries in the Netherlands. J Trauma 1997 42 : 1116 23.
13. Verstappen SM, Boonen A, Verkleij H, et al. Productivity costs among patients with rheumatoid arthritis: the influence of methods and sources to value loss of productivity. Ann Rheum Dis 2005 64 : 1754 60.
14. Brown MC, Nimmerrichter AA, Guest JF. Cost-effectiveness of mirtazapine compared to amitriptyline and fluoxetine in the treatment of moderate and severe depression in austria. Eur Psychiatry 1999 14 : 230 44.
15. Fernandez JL, Montgomery S, Francois C. Evaluation of the cost effectiveness of escitalopram versus venlafaxine XR in major depressive disorder. Pharmacoeconomics 2005 23 : 155 67.
16. Goossens ME, Rutten-Van Molken MP, Kole-Snijders AM, et al. Health economic assessment of behavioural rehabilitation in chronic low back pain: a randomised clinical trial. Health Econ 1998 7 : 39 51.
17. Li X, Gignac MA, Anis AH. The indirect costs of arthritis resulting from unemployment, reduced performance, and occupational changes while at work. Med Care 2006 44 : 304 10.
18. Osterhaus JT, Gutterman DL, Plachetka JR. Healthcare resource and lost labour costs of migraine headache in the US. Pharmacoeconomics 1992 2 : 67 76.
19. Schermer TR, Thoonen BP, van den Boom G, et al. Randomized controlled economic evaluation of asthma self-management in primary health care. Am J Respir Crit Care Med 2002 166 : 1062 72.
20. Wong JB, Singh G, Kavanaugh A. Estimating the cost-effectiveness of 54 weeks of infliximab for rheumatoid arthritis. Am J Med 2002 113 : 400 8.
21. Byford S, Knapp M, Greenshields J, et al. Cost-effectiveness of brief cognitive behaviour therapy versus treatment as usual in recurrent deliberate self-harm: a decision-making approach. Psychol Med 2003 33 : 977 86.
22. Kobelt G, Jonsson L, Young A, Eberhardt K. The cost-effectiveness of infliximab (Remicade) in the treatment of rheumatoid arthritis in Sweden and the United Kingdom based on the ATTRACT study. Rheumatology (Oxford) 2003 42 : 326 35.
23. Puolakka K, Kautiainen H, Pekurinen M, et al. Monetary value of lost productivity over a five year follow up in early rheumatoid arthritis estimated on the basis of official register data on patients' sickness absence and gross income: experience from the FIN-RACo trial. Ann Rheum Dis 2006 65 : 899 904.
24. Wade AG, Toumi I, Hemels ME. A pharmacoeconomic evaluation of escitalopram versus citalopram in the treatment of severe depression in the United Kingdom. Clin Ther 2005 27 : 486 96.
25. Fritzell P, Hagg O, Jonsson D, Nordwall A. Cost-effectiveness of lumbar fusion and nonsurgical treatment for chronic low back pain in the Swedish Lumbar Spine Study: a multicenter, randomized, controlled trial from the Swedish Lumbar Spine Study Group. Spine 2004 29 : 421 34 discussion Z3.
26. Lambert CM, Hurst NP, Forbes JF, et al. Is day care equivalent to inpatient care for active rheumatoid arthritis? Randomised controlled clinical and economic evaluation. BMJ 1998 316 : 965 9.
27. Schadlich PK, Zeidler H, Zink A, et al. Modelling cost effectiveness and cost utility of sequential DMARD therapy including leflunomide in rheumatoid arthritis in Germany. I. Selected DMARDs and patient-related costs. Pharmacoeconomics 2005 23 : 377 93.
28. APA. Diagnostic and Statistical Manual of Mental Disorders (4th ed.). Washington : American Psychiatric Association, 1994.
29. Samuels J, Eaton WW, Bienvenu OJ 3rd, et al. Prevalence and correlates of personality disorders in a community sample. Br J Psychiatry 2002 180 : 536 42.
30. Paris J. The treatment of borderline personality disorder in light of the research on its long term outcome. Can J Psychiatry 1993 38 (Suppl. 1 S28 34.
31. van Asselt AD, Dirksen CD, Arntz A, Severens JL. The cost of borderline personality disorder: societal cost of illness in BPD-patients. Eur Psychiatry 2007 22 : 354 61.
32. Giesen-Bloo J, van Dyck R, Spinhoven P, et al. Outpatient psychotherapy for borderline personality disorder: randomized trial of schema-focused therapy vs. transference-focused psychotherapy. Arch Gen Psychiatry 2006 63 : 649 58.
33. Oostenbrink JB, Bouwmans CAM, Koopmanschap MA, Rutten FF. Manual for Cost-Research. Methods and Unit Prices for Economic Evaluations in Healthcare (in Dutch). Actualised Version. Amstelveen : College voor zorgverzekeringen, 2004.
34. Dutch Central Bureau for Statistics. Available from: http://www.cbs.nl [Accessed January 10, 2006].
35. Briggs AH, Wonderling DE, Mooney CZ. Pulling cost-effectiveness analysis up by its bootstraps: a non-parametric approach to confidence interval estimation. Health Econ 1997 6 : 327 40.
36. Efron B, Tibshirani RJ. An Introduction to the Bootstrap. Londen : Chapmann & Hall, 1993.
37. Ament A, Evers S. Cost of illness studies in health care: a comparison of two cases. Health Policy 1993 26 : 29 42.
38. Polder JJ, Meerding WJ, Bonneux L, van der Maas PJ. Healthcare costs of intellectual disability in the Netherlands: a cost-of-illness perspective. J Intellect Disabil Res 2002 46 (Pt 2 168 78.
39. Rice DP, Miller LS. The economic burden of affective disorders. Br J Psychiatry Suppl 1995 Apr (27 s34 s42.
40. Fenwick E, Byford S. A guide to cost-effectiveness acceptability curves. Br J Psychiatry 2005 187 : 106 8.
41. Koopmanschap M, Burdorf A, Jacob K, et al. Measuring productivity changes in economic evaluation: setting the research agenda. Pharmacoeconomics 2005 23 : 47 54.